Table 1.

Commonly prescribed anticancer agents with summary of respective cardiotoxicity profiles

Class	Commonly Prescribed Agents	Trade Name	Incidence of Cardiotoxicitya (%) (Incidence of Left Ventricular Dysfuntion -%)	Reversibility
Anthracyclines	Doxorubicin Epirubicin	Adriamycin Ellence	Dose dependent; up to 26b	+
HER-2 targeted therapies
A. Monoclonal Antibodies	Trastuzumab	Herceptin	4.5c (up to 30% with asymptomatic cardiomyopathy)	+++
B. TKIs	Lapatinib	Tykerb	1.5–2.2g	Uncertain
VSP inhibitors
A. Monoclonal Antibodies	Bevacizumab	Avastin	2.2h	Uncertain
B. TKIs	Sorafenib Sunitinib	Nexavar Sutent	2.1d 4.1e	+++
Other Tyrosine Kinase Inhibitors (TKIs)	Imatinib	Gleevec	1.7f	Uncertain

Abbreviations: HER2, human epidermal growth factor receptor 2; TKI, tyrosine kinase inhibitor; VSP, vascular endothelial growth factor signaling pathway.

^aNote: Definitions of cardiotoxicity used by sources vary, limiting direct comparisons of incidence between agents. Reversibility indicates the percentage of patients who have cardiomyopathy reversibility after cessation of drug treatment and/or initiation of cardioprotective medications. “+” denotes least likely to reverse and “++++” most reversible. We additionally suggest changing the class grades as follow: anthracyclines “+”, Her-2 receptor targeted therapies “+++” and TKIs under VSP inhibitors (see below for clarification of table 1) “+++”.

^bJensen. Semin Oncol. 2006;33:S15–21.

^cSuter, Procter M, van Veldhuisen DJ, et al. J Clin Oncol. 2007:25:3859–65.

^dEscudier, Eisen T, Stadler WM, et al. N Engl J Med. 2007;356(2):125.

^eRichards, Je Y, Schutz FA, et al. J Clin Oncol. 2011;29(25):3450.

^fAtallah, Durand JB, Kantarjian H, et al. Blood. 2007;110(4):1233.

^gPerez, Koehler M, Byrne J, et al. Mayo Clin Proc. 2008;83(6):679.

^hBrana Choueiri TK, Mayer EL, Je Y, et al. J Clin Oncol. 2011;29(6):632–8.